Top Markets
#1 Islamic Coin Islamic Coin +151.50%
#2 DOVU DOVU +48.64%
#3 Akedo Akedo +46.30%
#4 Black Phoenix Black Phoenix +34.55%
#5 Velvet Velvet +32.25%
#6 DoubleZero DoubleZero +19.36%
#7 Cross Cross +16.34%
#8 Cap Cap +15.21%
#9 Tutorial Tutorial +13.37%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.43%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Kedudukan dalam Saham #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Harga Saham
$17.15
Disegerakkan terakhir: 2026-08-03
Modal Pasaran
$6.51M
Perubahan (1 hari)
9.80%
Perubahan (1 tahun)
289.77%
Negara
US
Perdagangan Galera Therapeutics, Inc. (GRTX)

Kategori

Healthcare
Nisbah P/E bagi Galera Therapeutics, Inc. (GRTX)
Nisbah P/E pada August 2026 TTM: 0.05
Menurut laporan kewangan dan harga saham terkini Galera Therapeutics, Inc., nisbah P/E semasa (TTM) ialah 0.05. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak -0.11.
Sejarah nisbah P/E bagi Galera Therapeutics, Inc. dari 2017 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
2026 (TTM) 0.05 -139.54%
2024 -0.13 20.44%
2023 -0.11 -83.10%
2022 -0.65 -55.87%
2021 -1.47 -57.12%
2020 -3.43 -45.48%
2019 -6.29 -35.93%
2018 -9.81 -98.74%
2017 -775.87 0.00%
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 54,468.48%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 60,491.83%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 37,446.11%
BE
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.